new glp-1 drugs in development Drugs: 6 Things We've Learned About Their Effects GLP-1 Drugs Market Size to
Description
GLP-1s role in neuroprotection: A systematic review
Epidemiol Health 40:e2018062
A further study presented at Digestive Disease Week 2025 of 993 patients found GLP-1RA to be associated with a statistically significant increase in clinical remission rates (HBI or Mayo score) at 3 months numerical at 6 and 12 months without an increase in side-effects
p = 0.0001), 12 months: 0.47 (95% CI: 0.38, 0.58
GLP-1RA cause weight loss in a dose-dependent manner, possibly through early satiety and delayed gastric emptying
doi: 10.2337/diabetes.52.7.1786 [DOI] [PubMed] [Google Scholar] 121
